Multiple major Chinese pharmaceutical enterprises are actively sourcing licensing opportunities for novel therapeutics with mature clinical progress. Our core target assets include fully approved drugs and candidates currently in Phase III clinical trials, for exclusive commercialization rights within mainland China.
Core Screening Criteria
- Asset Stage
- Commercialized medicines with official marketing approval in overseas markets
- Novel drugs completing or undergoing Phase III global clinical studies with promising efficacy and safety profiles
- Therapeutic Areas
Priority fields: oncology, autoimmune diseases, central nervous system disorders, metabolic diseases, rare diseases and anti-infectives
- Competitive Advantages Preferred
Differentiated mechanisms of action, best-in-class or first-in-class positioning, solid clinical trial data, and clear intellectual property protection.
Expected Cooperation Scope
We intend to obtain exclusive China rights covering development, registration, manufacturing and sales. Flexible transaction structures are acceptable, including upfront payments, milestone installments and tiered royalties aligned with commercial performance.
Our Strengths
Our partnered Chinese pharma partners possess robust domestic clinical trial networks, full NMPA registration capabilities, nationwide commercial sales channels, and abundant capital reserves to rapidly launch and scale up target drugs after licensing.
Contact Intent
We welcome biotech and pharmaceutical holders worldwide to share non-confidential deck for preliminary evaluation.
If you are interested in this opportunity, please contact DrugTimes BD Team by email (BD@drugtimes.cn).
Thank you very much!
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
